Thoracic – Original SubmissionImpact of Surgeon Volume on Outcomes of Older Stage I Lung Cancer Patients Treated via Video-assisted Thoracoscopic Surgery
Introduction
Patients with early-stage non–small cell lung cancer (NSCLC) are usually treated with lobectomy. Segmentectomy or wedge resections are also frequently used to treat patients with borderline lung function. Although the traditional technique to conduct these surgeries is via open thoracotomy, more recently, video-assisted thoracoscopic surgery (VATS) has been rapidly adopted as an approach for performing resections for early-stage lung cancer (Supplementary material). Current data suggest that VATS is associated with better perioperative outcomes and may be equivalent to open resection in terms of long-term oncological results.1, 2, 3
Several studies have shown that cancer patients whose surgical treatments are performed by surgeons with high case volumes have improved outcomes.4, 5, 6, 7 These studies, however, have not routinely included patients with lung cancer. The majority of studies focused on lung cancer have evaluated the association between hospital volume and patients' outcomes.4, 8 The few studies that have examined the importance of surgeon volume have primarily focused on postoperative mortality and reported mixed results.9, 10, 11 Lack of data regarding the relationship between surgeon volume and VATS is a challenge for generating recommendations for training certifications as well as national policy regarding organization of surgical care and referral patterns.
In this study, we used population-based data from a national cancer registry to evaluate the effect of surgeon volume on perioperative outcomes and long-term survival of older stage I NSCLC patients treated with VATS lobectomy, segmentectomy, or wedge resection.
Section snippets
Methods
Study subjects were identified from the Surveillance, Epidemiology, and End Results (SEER) database, a registry maintained by the National Cancer Institute that contains information on all new cases of cancer from several geographic areas of the United States.12 For patients ≥65 years of age in SEER, their cancer information has been linked to Medicare claims to create the SEER-Medicare database.12 The study cohort consisted of primary cases of pathologically confirmed, stage I NSCLC diagnosed
Results
We identified 2295 stage I NSCLC patients from SEER-Medicare databases who were treated with VATS resection between 2000 and 2010. Among the entire cohort, 67% underwent VATS lobectomy, 5% VATS segmentectomy, and 28% VATS wedge resection. The numbers of patients in each volume category were 774 (34%), 776 (34%), and 745 (32%) in the low-, intermediate-, and high-volume category, respectively. Baseline patient and physician characteristics of patients treated by low-, intermediate-, and
Discussion
VATS has been increasingly adopted as an approach for the treatment of early-stage lung cancers. To date, limited data exist regarding the surgeon volume-outcome relationship for lung cancer patients undergoing VATS. Using population-based data, we found that patients treated by surgeons with high volume of VATS resections had significantly improved perioperative outcomes and long-term survival. These data provide strong evidence that has the potential to impact training, accreditation, and
Acknowledgments
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.
References (32)
- et al.
Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer
J Thorac Cardiovasc Surg
(2009) - et al.
Thoracoscopic lobectomy: Report on safety, discharge independence, pain, and chemotherapy tolerance
J Thorac Cardiovasc Surg
(2008) - et al.
Video-assisted thoracic surgery lobectomy: Report of CALGB 39802–A prospective, multi-institution feasibility study
J Clin Oncol
(2007) - et al.
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection
J Natl Cancer Inst
(2006) - et al.
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection
J Surg Oncol
(2003) - et al.
High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec
World J Urol
(2015) - et al.
Volume-outcome associations in head and neck cancer treatment: A systematic review and meta-analysis
Head Neck
(2014) - et al.
The influence of hospital volume on survival after resection for lung cancer
N Engl J Med
(2001) - et al.
The impact of hospital and surgeon volume on the 30-day mortality of lung cancer surgery: A nation-based reappraisal
J Thorac Cardiovasc Surg
(2014) - et al.
The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: A systematic review and meta-analysis
J Thorac Oncol
(2012)
Surgeons' volume-outcome relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques
Minim Invasive Surg
Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population
Med Care
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol
Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: Observational cohort study
BMJ
The revised TNM staging system for lung cancer
Ann Thorac Cardiovasc Surg
Use of SEER-Medicare data for measuring cancer surgery
Med Care
Cited by (0)
Dr Wisnivesky is a member of the research board of EHE International, and has received consultant honorarium from BMS, Quintiles, and Merck, and a research grant from Aventis Pharmaceutical. Drs Smith and Wolf, and author Mhango have no commercial interests to disclose.
Funding source: This study was supported by the Agency for Health Care Research and Quality (R01HS019670-01). Dr Smith was supported by the Clinical Translational and Science Award (KL2TR000069).